Abstract
Lipid markers are well established predictors of vascular disease. The most frequently measured lipid variables are total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglycerides. In this review we consider the predictive value of these variables and other more specialised related tests. We also discuss the effect of lipid altering drugs on these markers. The interaction of other vascular risk factors and the lipid effects of non-lipid altering drugs (e.g. blood pressure lowering agents) are also briefly described. Similarly, we discuss the effects of lipid lowering drugs on non-lipid vascular risk factors. Finally, we briefly consider the effect of altering the lipid profile on surrogate markers and events associated with atherosclerosis.
Keywords: coronary heart disease, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, lipids, total cholesterol, apolipoproteins, lipid lowering drugs
Current Pharmaceutical Design
Title: The Predictive Value of Lipid Markers in Vascular Disease
Volume: 11 Issue: 17
Author(s): H. J. Milionis, S. S. Daskalopoulou, M. Elisaf and D. P. Mikhailidis
Affiliation:
Keywords: coronary heart disease, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, lipids, total cholesterol, apolipoproteins, lipid lowering drugs
Abstract: Lipid markers are well established predictors of vascular disease. The most frequently measured lipid variables are total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglycerides. In this review we consider the predictive value of these variables and other more specialised related tests. We also discuss the effect of lipid altering drugs on these markers. The interaction of other vascular risk factors and the lipid effects of non-lipid altering drugs (e.g. blood pressure lowering agents) are also briefly described. Similarly, we discuss the effects of lipid lowering drugs on non-lipid vascular risk factors. Finally, we briefly consider the effect of altering the lipid profile on surrogate markers and events associated with atherosclerosis.
Export Options
About this article
Cite this article as:
Milionis J. H., Daskalopoulou S. S., Elisaf M. and Mikhailidis P. D., The Predictive Value of Lipid Markers in Vascular Disease, Current Pharmaceutical Design 2005; 11 (17) . https://dx.doi.org/10.2174/1381612054367409
DOI https://dx.doi.org/10.2174/1381612054367409 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Induced Hypokalaemia
Current Drug Safety Imaging Subclinical Atherosclerosis: Where Do We Stand?
Current Cardiology Reviews Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis
Current Drug Safety Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics
Current Drug Safety Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States
Cardiovascular & Hematological Disorders-Drug Targets Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Poly-Pharmacy Among the Elderly: Analyzing the Co-Morbidity of Hypertension and Diabetes
Current Pharmaceutical Design Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets The Association Between Diabetes and Cognitive Function in Later Life
Current Aging Science Cardiovascular Remodeling Induced by Passive Smoking
Inflammation & Allergy - Drug Targets (Discontinued) Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors
Current Medicinal Chemistry Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued)